Aquestive Therapeutics Inc. (AQST) Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Aquestive Therapeutics Provides Business Update
October 9, 2023 8:00 AM EDTReceives positive feedback from FDA on pivotal study protocol for Anaphylm (epinephrine) Sublingual FilmReaffirms fourth quarter 2023 Anaphylm pivotal Phase 3 study start and first quarter 2024 topline data readoutOutlines expected remaining activities for Anaphylm program prior to NDA submissionIndicates FDA review of Libervant (diazepam) Buccal Film NDA on track with no open questions Anticipates increasing 2023 revenue and decreasing non-GAAP adjusted EBITDA loss guidance in upcoming earnings... More
